Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 30, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-10-29

Reporting Person: Murphy Polly A. (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series D Convertible Preferred Stock	$		Common Stock (7122)		Indirect
Series D-1 Convertible Preferred Stock	$		Common Stock (4173)		Indirect
Stock Option (Right to Buy)	$6.84	2030-08-19	Common Stock (80000)		Direct

Footnotes

F1: Each share of Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F2: The option vests and becomes exercisable in 36 equal monthly installments following August 17, 2020.